{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 42,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "other",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/21",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.502,
        "x": 0.32,
        "y": 0.795
      },
      "kind": "callout",
      "text": "103 subjects enrolled (FPFV Apr 2021 to LPLV Aug 2022)\nTopline data announced in January 2023",
      "attrs": {},
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f0d6c14-0ef8-4873-84b0-6211ecd61bdd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.401,
        "w": 0.359,
        "x": 0.301,
        "y": 0.313
      },
      "kind": "diagram",
      "text": "Randomization 1:1 Week 0 Week 4 Week 12 Week 24 Primary Endpoint APX3330 600mg/day (BID) Placebo BID",
      "attrs": {},
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afc3f66f-9737-42e8-be5a-19b2adec3acd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.065,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee0a2564-dbc1-44f4-aaed-aae1c9f4f84e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.516,
        "w": 0.283,
        "x": 0.677,
        "y": 0.259
      },
      "kind": "list",
      "text": "Primary:\n% subjects with ≥ 2 step improvement on DRSS (Diabetic Retinopathy Severity Scale¹) at week 24\nSecondary:\nDRSS improvement ≥1, ≥2, ≥3, ≥4 study eye, fellow eye, binocular\nDRSS worsening ≥1, ≥2, ≥3, ≥4, study eye, fellow eye, binocular\nProgression to vision threatening complications\nCentral subfield thickness (CST)\nBest Corrected Distance Visual Acuity (BCDVA)\nDME fellow eye status\nSafety and tolerability\nExploratory:\nInflammatory cytokines",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fc00d97-d980-414b-a264-c5ff6de1985e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.603,
        "w": 0.269,
        "x": 0.04,
        "y": 0.259
      },
      "kind": "list",
      "text": "25 US sites\nN = 103 participants with moderately severe to severe NPDR or mild PDR (DRSS 47, 53, 61)\nKey inclusion:\n≥ 18 years of age\nDRSS 47, 53, or 61\nNoncentral DME permitted²\nETDRS BCVA ≥ 60 letters (20/63)\nKey exclusion:\nOCT CST >320 µm²\nCenter involved DME allowed in fellow eye\nAnti-VEGF within past 6 months³\nHbA1c ≥ 12.0%",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fb983a7-4db4-4870-8c13-2cb0a0f1246f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.69,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Multi-center, Randomized, Double-Masked, Placebo-Controlled 24-Week Trial",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b538b5e2-2f64-4587-af60-4b4dfc0ffb3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.509,
        "x": 0.116,
        "y": 0.905
      },
      "kind": "source-note",
      "text": "1. By Central Reading Center\n2. Center-Involved DME in Fellow Eye is Acceptable\n3. Includes Systemic or IVT VEGF\nwww.clinicaltrials.gov (NCT04692688); Eylea® is registered trademark of Regeneron\nNPDR = non-proliferative diabetic retinopathy PDR = proliferative diabetic retinopathy",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f3aa6e4-4405-4a9a-923a-2011914db7be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.899,
        "x": 0.049,
        "y": 0.058
      },
      "kind": "title",
      "text": "ZETA-1: Phase 2 Trial of Oral APX3330 in Subjects With Diabetic Retinopathy",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c400dda-119c-4ee1-a9d8-8b07da66784b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 17,
      "beatId": "65814d93-901f-41c1-8ee8-b0d5c8ea9369",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 17-28 provide clinical trial results and data for APX3330",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}